These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 11179903)

  • 21. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
    Mizokami A; Koh E; Fujita H; Maeda Y; Egawa M; Koshida K; Honma S; Keller ET; Namiki M
    Cancer Res; 2004 Jan; 64(2):765-71. PubMed ID: 14744796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays.
    Kim HJ; Park YI; Dong MS
    Toxicol In Vitro; 2006 Oct; 20(7):1159-67. PubMed ID: 16621434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.
    Veldscholte J; Berrevoets CA; Ris-Stalpers C; Kuiper GG; Jenster G; Trapman J; Brinkmann AO; Mulder E
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):665-9. PubMed ID: 1562539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
    J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells.
    Simard J; Veilleux R; de Launoit Y; Haagensen DE; Labrie F
    Cancer Res; 1991 Aug; 51(16):4336-41. PubMed ID: 1868457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
    Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H
    Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
    Attardi BJ; Burgenson J; Hild SA; Reel JR
    Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
    Umekita Y; Hiipakka RA; Kokontis JM; Liao S
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11802-7. PubMed ID: 8876218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.
    Zhao XY; Boyle B; Krishnan AV; Navone NM; Peehl DM; Feldman D
    J Urol; 1999 Dec; 162(6):2192-9. PubMed ID: 10569618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
    Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
    Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.
    Tepper CG; Boucher DL; Ryan PE; Ma AH; Xia L; Lee LF; Pretlow TG; Kung HJ
    Cancer Res; 2002 Nov; 62(22):6606-14. PubMed ID: 12438256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.
    Zhao XY; Malloy PJ; Krishnan AV; Swami S; Navone NM; Peehl DM; Feldman D
    Nat Med; 2000 Jun; 6(6):703-6. PubMed ID: 10835690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase.
    Shen R; Sumitomo M; Dai J; Harris A; Kaminetzky D; Gao M; Burnstein KL; Nanus DM
    Endocrinology; 2000 May; 141(5):1699-704. PubMed ID: 10803579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor.
    Rajamahanty S; Alonzo C; Aynehchi S; Choudhury M; Konno S
    J Biomed Sci; 2010 Jan; 17(1):5. PubMed ID: 20102617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
    Ben Jemaa A; Sallami S; Céraline J; Oueslati R
    Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y; Wolff DW; Lin MF; Tu Y
    Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
    Wetherill YB; Fisher NL; Staubach A; Danielsen M; de Vere White RW; Knudsen KE
    Cancer Res; 2005 Jan; 65(1):54-65. PubMed ID: 15665279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.